NMRA logo

NMRA
Neumora Therapeutics Inc.

1,155
Mkt Cap
$371.36M
Volume
765,836.00
52W High
$3.65
52W Low
$0.611
PE Ratio
-1.41
NMRA Fundamentals
Price
$2.04
Prev Close
$2.08
Open
$2.09
50D MA
$2.72
Beta
1.81
Avg. Volume
1.06M
EPS (Annual)
-$1.45
P/B
3.42
Rev/Employee
$0.00
$164.95
Loading...
Loading...
News
all
press releases
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)
Guggenheim reiterated a "buy" rating and issued a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday...
MarketBeat·11d ago
News Placeholder
Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday...
MarketBeat·11d ago
News Placeholder
Neumora Therapeutics Sees Unusually Large Options Volume (NASDAQ:NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) was the recipient of some unusual options trading on Monday. Traders bought 2,812 call options on the company. This represents an increase of 309% compared to the typical daily volume of 687 call options...
MarketBeat·12d ago
News Placeholder
Neumora Therapeutics Q4 Earnings Call Highlights
Neumora Therapeutics (NASDAQ:NMRA) outlined clinical and pipeline updates alongside its fourth-quarter and full-year 2025 financial results, highlighting multiple anticipated data catalysts in 2026...
MarketBeat·12d ago
News Placeholder
Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·12d ago
News Placeholder
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages
Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have received a consensus rating of "Hold" from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, one has issued a...
MarketBeat·14d ago
News Placeholder
Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
read more...
Benzinga·15d ago
News Placeholder
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (Neumora or the Company) (NASDAQ...
Business Wire·23d ago
News Placeholder
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Down 13.7% in February
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 5,216,610 shares...
MarketBeat·25d ago
<
1
2
...
>

Latest NMRA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.